Table 2 |
|||||||
|
Study characteristics |
|||||||
|
Variables |
Total |
E-mail available* |
E-mail not available |
p** |
Responders |
Non-responders |
p |
|
|
|||||||
|
Recruiting status of study |
1500 |
1299 |
201 |
0.15 |
282 |
1017 |
0.68 |
|
Recruiting |
1375 (91.7) |
1196 (92.1) |
179 (89.0) |
258 (91.5) |
938 (92.23) |
||
|
Not yet |
125 (8.3) |
103 (7.9) |
125 (8.3) |
24 (8.5) |
79 (7.8) |
||
|
Type of sponsor |
<0.001 |
<0.001 |
|||||
|
NIH |
288 (19.2) |
207 (15.9) |
81 (40.3) |
21 (7.4) |
186 (18.3) |
||
|
Other |
1212 (80.8) |
1092 (84.1) |
120 (59.7) |
261 (92.5) |
831 (81.7) |
||
|
Study condition according to ICD 10 |
<0.001 |
0.03 |
|||||
|
Infections |
69 (4.6) |
64 (4.9) |
5 (2.5) |
22 (7.8) |
42 (4.1) |
||
|
Oncology |
608 (40.5) |
474 (36.5) |
134 (66.7) |
73 (25.9) |
401 (39.4) |
||
|
Haematology |
23 (1.5) |
19 (1.5) |
4 (2.0) |
3 (1.1) |
16 (1.6) |
||
|
Endocrinologic diseases |
85 (5.7) |
79 (6.1) |
6 (3.0) |
21 (7.4) |
58 (5.7) |
||
|
Psychiatric diseases |
119 (7.9) |
109 (8.4) |
10 (4.9) |
28 (9.9) |
81 (8.0) |
||
|
Neurologic diseases |
62 (4.1) |
58 (4.6) |
4 (2.0) |
14 (5.0) |
44 (4.3) |
||
|
Eye |
12 (0.8) |
2 (1.0) |
10 (0.8) |
2 (0.7) |
8 (0.8) |
||
|
Ear |
2 (0.1) |
2 (0.1) |
0 (0.0) |
1 (0.3) |
1 (0.1) |
||
|
Cardiovascular diseases |
123 (8.2) |
118 (9.1) |
5 (2.5) |
30 (10.6) |
88 (8.6) |
||
|
Lung diseases |
59 (3.9) |
53 (4.1) |
6 (3.0) |
10 (3.5) |
43 (4.2) |
||
|
Digestive diseases |
43 (3.3) |
4 (2.0) |
47 (3.1) |
15 (5.2) |
28 (2.7) |
||
|
Skin |
19 (1.3) |
18 (1.4) |
1 (0.5) |
3 (1.1) |
15 (1.5) |
||
|
Musculoskeletal disorders |
51 (3.4) |
48 (3.7) |
3 (1.5) |
12 (4.3) |
36 (3.5) |
||
|
Urology |
76 (5.1) |
72 (5.5) |
4 (2.0) |
20 (7.1) |
52 (5.1) |
||
|
Pregnancy |
26 (1.7) |
23 (1.8) |
3 (1.5) |
5 (1.8) |
18 (1.8) |
||
|
Perinatal disorders |
10 (0.7) |
10 (0.8) |
0 (0.0) |
3 (1.1) |
7 (0.7) |
||
|
Labour |
2 (0.1) |
2 (0.1) |
0 (0.0) |
1 (0.3) |
1 (0.1) |
||
|
Trauma |
39 (2.6) |
35 (2.7) |
4 (2.0) |
6 (2.1) |
29 (2.8) |
||
|
Extern |
1 (0.1) |
1 (0.1) |
0 (0.0) |
1 (0.3) |
0 (0.0) |
||
|
Other |
67 (4.5) |
61 (4.7) |
6 (3.0) |
12 (4.3) |
49 (4.8) |
||
|
Study intervention |
<0.001 |
0.10 |
|||||
|
Drug |
895 (59.7) |
741 (57.0) |
154 (76.6) |
143 (50.7) |
598 (58.8) |
||
|
Procedure |
231 (15.4) |
211 (16.2) |
20 (9.9) |
55 (19.5) |
156 (15.3) |
||
|
Behaviour |
112 (7.5) |
107 (8.2) |
5 (2.5) |
32 (11.3) |
75 (7.4) |
||
|
Device |
64 (4.3) |
62 (4.8) |
2 (1.0) |
14 (5.0) |
48 (4.7) |
||
|
Vaccine |
17 (1.1) |
12 (0.9) |
5 (2.5) |
3 (1.1) |
9 (0.9) |
||
|
Gene therapy |
5 (0.3) |
4 (0.3) |
1 (0.5) |
0 (0.0) |
4 (0.4) |
||
|
Other/not applicable |
176 (11.7) |
162 (12.5) |
14 (7.0) |
35 (12.4) |
127 (12.5) |
||
|
Study phase |
<0.001 |
<0.01 |
|||||
|
Phase I |
137 (9.1) |
113 (8.7) |
24 (11.9) |
19 (6.7) |
94 (9.2) |
||
|
Phase II |
357 (23.8) |
281 (21.6) |
76 (37.8) |
45 (16.0) |
236 (23.2) |
||
|
Phase III |
230 (15.3) |
206 (15.9) |
24 (11.9) |
51 (8.1) |
155 (15.2) |
||
|
Phase IV |
177 (11.8) |
168 (12.9) |
9 (4.5) |
48 (17.0) |
120 (11.8) |
||
|
Phase I/II |
72 (4.8) |
56 (4.3) |
16 (8.0) |
6 (2.1) |
50 (4.9) |
||
|
Phase II/III |
43 (2.9) |
35 (2.7) |
8 (4.0) |
6 (2.1) |
29 (2.8) |
||
|
Not applicable |
484 (32.3) |
440 (33.9) |
44 (21.9) |
107 (37.9) |
333 (32.7) |
||
|
|
|||||||
|
* E-mail address of principal investigator ** Chi-squared test Categories with less than six counts overall were added to category "Other" or "Other/not applicable" for the chi-square test. |
|||||||
|
Scherer and Trelle BMC Health Services Research 2008 8:18 doi:10.1186/1472-6963-8-18 |
|||||||
